The regulatory landscape for actively personalized cancer immunotherapies.

The article focuses on the regulatory challenges associated with the introduction of innovative personalized medicine for treatment of cancer. It informs that addressing the regulatory challenges requires a differentiated look at quality, preclinical and clinical aspects. It adds that regulatory principles that are applied to the manufacture and quality control of actively personalized vaccines (APVACs) are similar to those relevant for autologous cell therapies.